Liuying

Running trials

• Recruiting

  A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

  NCT07098338· Phase 2· Source

• Active, not recruiting

  Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

  NCT05261399· Phase 3· Source

• Recruiting

  Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  NCT05061550· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting

Researchers

No researcher is linked here yet.